What is the share price of Beta Drugs Ltd (BETA) today?
The share price of BETA as on 14th July 2025 is ₹1739.95. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Beta Drugs Ltd (BETA) share?
The past returns of Beta Drugs Ltd (BETA) share are- Past 1 week: 0.62%
- Past 1 month: -2.45%
- Past 3 months: -5.95%
- Past 6 months: -0.00%
- Past 1 year: 50.56%
- Past 3 years: 176.39%
- Past 5 years: 2710.69%
What are the peers or stocks similar to Beta Drugs Ltd (BETA)?
The peers or stocks similar to Beta Drugs Ltd (BETA) include:What is the market cap of Beta Drugs Ltd (BETA) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Beta Drugs Ltd (BETA) is ₹1756.40 Cr as of 14th July 2025.What is the 52 week high and low of Beta Drugs Ltd (BETA) share?
The 52-week high of Beta Drugs Ltd (BETA) is ₹2215.24 and the 52-week low is ₹1143.81.What is the PE and PB ratio of Beta Drugs Ltd (BETA) stock?
The P/E (price-to-earnings) ratio of Beta Drugs Ltd (BETA) is 41.41. The P/B (price-to-book) ratio is 11.18.Which sector does Beta Drugs Ltd (BETA) belong to?
Beta Drugs Ltd (BETA) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Beta Drugs Ltd (BETA) shares?
You can directly buy Beta Drugs Ltd (BETA) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Beta Drugs Ltd
BETA Share Price
1,739.951.18% (-20.85)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
BETA Stock Scorecard
Performance
HighThe creamy layer - amongst the top performing stocks
Valuation
HighSeems to be overvalued vs the market average
Growth
AvgFinancials growth has been moderate for a few years
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
BETA Performance & Key Metrics
BETA Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| — | 11.18 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 37.43 | 6.45 | 0.80% |
BETA Analyst Ratings & Forecast
—
Analyst Ratings data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
BETA Company Profile
Beta Drugs Limited is a pharmaceutical formulation manufacturing company. It is engaged in developing, manufacturing and marketing of drug products for domestic and international customers. The Company also engaged manufacturing oncology products
SUNPHARMA
PE Ratio
36.94
36.94
1Y Return
6.08%
6.08%
Buy Reco %
87.10
87.10
CIPLA
PE Ratio
22.73
22.73
1Y Return
2.19%
2.19%
Buy Reco %
73.33
73.33
TORNTPHARM
PE Ratio
60.29
60.29
1Y Return
15.28%
15.28%
Buy Reco %
70.83
70.83
MANKIND
PE Ratio
55.89
55.89
1Y Return
25.50%
25.50%
Buy Reco %
81.25
81.25
DRREDDY
PE Ratio
18.40
18.40
1Y Return
7.97%
7.97%
Buy Reco %
50.00
50.00
BETA Forecast
BETA Forecasts
Forecast data is currently unavailable
Forecast data is currently unavailable
Price
Price Upside
Revenue
Revenue Growth
Earnings
Earnings Per Share
BETA
BETA
Income
Balance Sheet
Cash Flow
Annual Normal View
BETA Income Statement
BETA Income Statement
Annual Normal View
| Financial Year | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 50.81 | 66.30 | 91.22 | 116.62 | 184.60 | 227.86 | 297.07 | 368.79 | — | |||||||||
Raw Materials | 28.15 | 37.26 | 45.21 | 60.55 | 96.21 | 110.40 | 167.65 | 292.32 | — | |||||||||
| Power & Fuel Cost | 0.89 | 1.21 | 1.95 | 2.75 | 3.43 | 4.79 | 6.35 | |||||||||||
| Employee Cost | 1.26 | 3.80 | 6.95 | 8.32 | 12.10 | 17.08 | 20.14 | |||||||||||
| Selling & Administrative Expenses | 4.85 | 7.82 | 10.27 | 10.31 | 16.26 | 25.89 | 33.12 | |||||||||||
| Operating & Other expenses | 5.96 | 4.04 | 8.52 | 9.45 | 13.14 | 15.83 | 8.46 | |||||||||||
EBITDA | 9.70 | 12.17 | 18.32 | 25.24 | 43.46 | 53.87 | 61.35 | 76.47 | — | |||||||||
| Depreciation/Amortization | 1.85 | 2.84 | 3.76 | 6.87 | 7.25 | 10.41 | 9.78 | 12.51 | — | |||||||||
| PBIT | 7.85 | 9.33 | 14.56 | 18.37 | 36.21 | 43.46 | 51.57 | 63.96 | — | |||||||||
| Interest & Other Items | 1.01 | 1.43 | 2.59 | 2.42 | 1.90 | 2.41 | 2.82 | 6.99 | — | |||||||||
| PBT | 6.84 | 7.90 | 11.97 | 15.95 | 34.31 | 41.05 | 48.75 | 56.97 | — | |||||||||
| Taxes & Other Items | 0.07 | -0.14 | 2.56 | 4.23 | 9.48 | 10.34 | 12.32 | 14.55 | — | |||||||||
| Net Income | 6.77 | 8.04 | 9.41 | 11.72 | 24.83 | 30.71 | 36.43 | 42.42 | — | |||||||||
| EPS | 7.45 | 8.85 | 9.81 | 11.61 | 24.60 | 30.42 | 36.09 | 42.02 | — | |||||||||
| DPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | |||||||||
| Payout ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
BETA Company Updates
BETA Stock Peers
BETA Past Performance & Peer Comparison
BETA Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation-basic on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation-basic on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Beta Drugs Ltd | 41.41 | 11.18 | — |
| Sun Pharmaceutical Industries Ltd | 36.94 | 5.57 | 0.95% |
| Cipla Ltd | 22.73 | 3.83 | 1.08% |
| Torrent Pharmaceuticals Ltd | 60.29 | 15.18 | 0.94% |
BETA Stock Price Comparison
Compare BETA with any stock or ETFCompare BETA with any stock or ETF
BETA
BETA Holdings
BETA Shareholdings
BETA Promoter Holdings Trend
BETA Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
BETA Institutional Holdings Trend
BETA Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
BETA Shareholding Pattern
BETA Shareholding Pattern
BETA Shareholding History
BETA Shareholding History
Foreign Institutions
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases containing BETA stock
smallcases containing BETA stock
Looks like this stock is not in any smallcase yet.
BETA Events
BETA Events
BETA Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
BETA has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
BETA Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
BETA has not given any dividends in last 5 years
BETA Dividends
BETA Dividends
Hmm, looks like data is unavailable here. Please come back after some timeBETA Stock News & Opinions
BETA Stock News & Opinions
Articles & Videos
Corporate
Beta Drugs to conduct board meeting
Beta Drugs will hold a meeting of the Board of Directors of the Company on 15 May 2025.Powered by Capital Market - Live
2 months agoCapital Market - Live
Corporate
Beta Drugs announces board meeting date
Beta Drugs will hold a meeting of the Board of Directors of the Company on 27 March 2025.Powered by Capital Market - Live
3 months agoCapital Market - Live
Corporate
Beta Drugs to conduct board meeting
Beta Drugs will hold a meeting of the Board of Directors of the Company on 5 February 2025.Powered by Capital Market - Live
5 months agoCapital Market - Live
Corporate
Beta Drugs schedules EGM
Beta Drugs announced that an Extra Ordinary General Meeting (EGM) of the Company will be held on 21 December 2024 .Powered by Capital Market - Live
7 months agoCapital Market - Live
Corporate
Beta Drugs to conduct board meeting
Beta Drugs will hold a meeting of the Board of Directors of the Company on 6 November 2024Powered by Capital Market - Live
8 months agoCapital Market - Live
Corporate
Beta Drugs to conduct EGM
Beta Drugs announced that an Extra Ordinary General Meeting (EGM) of the Company will be held on 12 November 2024 .Powered by Capital Market - Live
8 months agoCapital Market - Live
Corporate
Beta Drugs schedules AGM
Beta Drugs announced that the 19th Annual General Meeting (AGM) of the company will be held on 30 September 2024.Powered by Capital Market - Live
10 months agoCapital Market - Live
Stock market update: Stocks that hit 52-week highs on NSE
1 year agoEconomic Times
बढ़ने और गिरने वाले SME's शेयर: Bright Solar, Nitiraj Engineers, Omfurn India, Beta Drugs
6 years agoCNBC Awaaz
Over the last 5 years, revenue has grown at a yearly rate of 32.23%, vs industry avg of 10.04%
Over the last 5 years, market share increased from 0.04% to 0.09%
Over the last 5 years, net income has grown at a yearly rate of 35.14%, vs industry avg of 19.67%